Loading

Please wait...

Egrifta

Generic Name: tesamorelin (TES a moe REL in)
Brand Names: Egrifta
Egrifta (tesamorelin) is used to reduce excess fat around the stomach that is caused by taking certain HIV medications. Includes Egrifta side effects, interactions and indications.
  • Prescription Settings
  • X
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.
  • Learn more

Egrifta Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Egrifta (tesamorelin) is made with growth hormone-releasing factor (GRF). Egrifta is used to reduce excess fat around the stomach that is caused by taking certain HIV medications. This condition is also called lipodystrophy (LYE-poe-DIS-troe-fee). Egrifta is not a weight-loss medication and should not be used to treat obesity. Egrifta can harm an unborn baby or cause birth defects. Do not use if you are pregnant. You should not use Egrifta if you are allergic to tesamorelin, or if you have a history of tumor or surgery of your pituitary gland, a history of head injury or radiation treatment. Learn more

Pickup / Home Delivery

USARx offers multiple ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price
    Local Pharmacy Pickup

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply
    Mail Order Home Delivery

    The easiest way to receive your medications.

Egrifta Side Effects

Note: This document contains side effect information about tesamorelin. Some of the dosage forms listed on this page may not apply to the brand name Egrifta.

In Summary

Common side effects of Egrifta include: injection site reaction, erythema at injection site, bruising at injection site, irritation at injection site, and pain at injection site. Other side effects include: limb pain, myalgia, peripheral edema, and decreased glucose tolerance. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to tesamorelin: subcutaneous powder for solution

Along with its needed effects, tesamorelin (the active ingredient contained in Egrifta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tesamorelin:

More common

  • Difficulty with moving
  • muscle pain or stiffness
  • pain in the arms or legs
  • pain in the joints

Less common

  • Blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • burning, numbness, pain, or tingling in all fingers except the smallest finger
  • chest pain
  • dizziness
  • fast, irregular, pounding, or racing heartbeat or pulse
  • headache
  • nervousness
  • pounding in the ears
  • slow or fast heartbeat
  • swelling of the joints
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet

Some side effects of tesamorelin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at injection site
  • muscle aching or cramping

Less common

  • Acid or sour stomach
  • belching
  • bone pain
  • discouragement
  • feeling of warmth
  • feeling sad or empty
  • heartburn
  • indigestion
  • irritability
  • itching skin
  • lack of appetite
  • loss of interest or pleasure
  • muscle spasms
  • nausea
  • night sweats
  • rash
  • redness of the face, neck, arms, and occasionally, upper chest
  • sleeplessness
  • stiffness of the joints
  • stomach discomfort, upset, or pain
  • strain in the muscles
  • sudden sweating
  • tiredness
  • trouble concentrating
  • trouble sleeping
  • unable to sleep
  • upper abdominal or stomach pain
  • vomiting

For Healthcare Professionals

Applies to tesamorelin: subcutaneous powder for injection

Musculoskeletal

Very common (10% or more): Arthralgia (13.3%)

Common (1% to 10%): Pain in extremity, myalgia, musculoskeletal pain, musculoskeletal stiffness, joint stiffness, muscle spasms, joint swelling, muscle strain

Local

Common (1% to 10%): Injection site erythema, injection site pruritus, injection site pain, injection site irritation, injection site hemorrhage, injection site urticaria, injection site swelling, injection site reaction, injection site rash

Nervous system

Common (1% to 10%): Paresthesia, hypoesthesia, carpal tunnel syndrome, peripheral neuropathy

Gastrointestinal

Common (1% to 10%): Nausea, vomiting, dyspepsia, abdominal pain upper

Metabolic

Common (1% to 10%): Diabetes

Uncommon (0.1% to 1%): Increased HbA1c

Cardiovascular

Common (1% to 10%): Palpitations, hypertension, hot flush

Psychiatric

Common (1% to 10%): Depression, insomnia

Dermatologic

Common (1% to 10%): Rash, pruritus, night sweats

Other

Common (1% to 10%): Peripheral edema, pain, chest pain, blood creatine phosphokinase increased

Immunologic

Very common (10% or more): Anti- tesamorelin (the active ingredient contained in Egrifta) IgG antibodies (49.5%)

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Egrifta (www.drugs.com/egrifta.html).